{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:12:52Z","timestamp":1782951172854,"version":"3.54.5"},"reference-count":63,"publisher":"PAGEPress Publications","issue":"2","license":[{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reumatismo"],"abstract":"<jats:p>Objective. Interstitial lung disease (ILD) is rare, but it is one of the most frequent extra-articular manifestations and a relevant cause of morbidity and mortality in rheumatoid arthritis (RA). Over the past few years, Janus kinase inhibitors (JAKis) have been reported to have promising efficacy in the treatment of active RA, but recent concerns have been raised about their safety profile, namely, malignancy and cardiovascular disease, limiting their use to certain patient categories.\nMethods. The objective of this narrative review is to summarize the current evidence of the efficacy and safety of JAKis in RA-ILD management, investigating a possible emerging role for this drug class in such a subset of patients.\nResults. Current studies focusing on JAKis in RA-ILD are scarce, but they globally report an overall stabilization of respiratory symptoms, functional data, and radiographic extension of ILD. In some cohorts, JAKis determined even an encouraging improvement in lung disease, and few reports presented good tolerability of JAKis in combination with antifibrotics. Concerning the safety profile, no significant increased risk of pulmonary infection has been reported.\nConclusions. Thus far, evidence regarding the role of JAKis in the treatment of RA-ILD remains relatively limited, and additional prospective studies are needed to better understand the place of JAKis, if any, in preventing\/stabilizing ILD in RA patients.<\/jats:p>","DOI":"10.4081\/reumatismo.2025.1754","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T08:13:56Z","timestamp":1738138436000},"source":"Crossref","is-referenced-by-count":1,"title":["Janus kinase inhibitors in rheumatoid arthritis-associated interstitial lung disease: where do we stand and what may be the future?"],"prefix":"10.4081","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7313-3520","authenticated-orcid":false,"given":"Beatrice","family":"Maranini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3074-4508","authenticated-orcid":false,"given":"Roberta","family":"Foti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3394-6298","authenticated-orcid":false,"given":"Moustapha","family":"Taha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0681-1472","authenticated-orcid":false,"given":"Veronica","family":"Venturelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1455-0818","authenticated-orcid":false,"given":"Andrea","family":"Lo Monaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0499-5773","authenticated-orcid":false,"given":"Marcello","family":"Govoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2549","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"key":"11126","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-019-0275-x"},{"key":"11127","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2014.12.004"},{"key":"11128","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201004-0622OC"},{"key":"11129","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211138"},{"key":"11130","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes262"},{"key":"11131","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-017-3781-7"},{"key":"11132","doi-asserted-by":"publisher","DOI":"10.1002\/art.27405"},{"key":"11133","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002777"},{"key":"11134","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2019.05.003"},{"key":"11135","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00008014"},{"key":"11136","doi-asserted-by":"publisher","DOI":"10.1002\/art.40904"},{"key":"11137","doi-asserted-by":"publisher","DOI":"10.1038\/srep14897"},{"key":"11138","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2008.101691"},{"key":"11139","unstructured":"ACR. 2023 Interstitial Lung disease guidelines. Available from: https:\/\/rheumatology.org\/interstitial-lung-disease-guideline."},{"key":"11140","doi-asserted-by":"publisher","DOI":"10.1016\/j.reumae.2022.03.004"},{"key":"11141","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00438-4"},{"key":"11142","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2020.1794103"},{"key":"11143","unstructured":"FDA. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death."},{"key":"11144","unstructured":"EMA. EMA\u2019s Safety Committee (PRAC). Janus Kinase Inhibitors\u2014PRAC Recommendation. 2022. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/janus-kinase-inhibitors-jaki."},{"key":"11145","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-011-1999-3"},{"key":"11146","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-903223\/v1"},{"key":"11147","doi-asserted-by":"publisher","DOI":"10.1016\/j.rcreue.2018.02.003"},{"key":"11148","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.269"},{"key":"11149","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12030957"},{"key":"11150","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-022-00936-w"},{"key":"11151","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-eular.4896"},{"key":"11152","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-024-00374-x"},{"key":"11153","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6652845"},{"key":"11154","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59111960"},{"key":"11155","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106748"},{"key":"11156","unstructured":"Charaja HJM, Luza ME, Leon DP. Interstitial lung disease improvement in patients with rheumatoid arthritis and tofacitinib. J Clin Rheumatol 2019; 25: S48."},{"key":"11157","doi-asserted-by":"publisher","DOI":"10.1080\/24725625.2021.1899372"},{"key":"11158","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25052682"},{"key":"11159","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001552"},{"key":"11160","unstructured":"ClinicalTrials.gov. Effects of tofacitinib vs methotrexate on rheumatoid arthritis interstitial lung disease (PULMORA). ClinicalTrials.gov. Identifier: NCT04311567. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04311567."},{"key":"11161","unstructured":"ClinicalTrials.gov. Tofacitinib in the treatment of rheumatoid arthritis-related interstitial lung disease. (RAILDTo). ClinicalTrials.gov Identifier: NCT05246293. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05246293."},{"key":"11162","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05854-w"},{"key":"11163","doi-asserted-by":"publisher","DOI":"10.1183\/1393003.congress-2017.PA893"},{"key":"11164","doi-asserted-by":"publisher","DOI":"10.1111\/imj.14670"},{"key":"11165","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.820163"},{"key":"11166","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa117"},{"key":"11167","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-021-00332-w"},{"key":"11168","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-eular.1420"},{"key":"11169","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222405"},{"key":"11170","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13853"},{"key":"11171","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-018-0097-3"},{"key":"11172","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126211"},{"key":"11173","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-021-04835-1"},{"key":"11174","unstructured":"Matsuno H, Atsumi T, Takei S, Tamura N, Harigai M, Fujii T, et al. Safety of baricitinib under clinical settings in patients with rheumatoid arthritis, using data from all-case post-marketing surveillance and spontaneous reports. Arthritis Rheumatol 2019; 71: 4197-8."},{"key":"11175","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2022-eahp.160"},{"key":"11176","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2017.03.033"},{"key":"11177","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129191"},{"key":"11178","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-019-1094-y"},{"key":"11179","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222543"},{"key":"11180","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02472-2018"},{"key":"11181","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00198013"},{"key":"11182","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-020-00938-z"},{"key":"11183","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2021.1862084"},{"key":"11184","unstructured":"Carrasco Cubero C, Chamizo Carmona E, Vela Casasempere P. Systematic review of the impact of drugs on diffuse interstitial lung disease associated with rheumatoid arthritis. Reumatol Clin 2020; S1699-258X(20)30111-X."},{"key":"11185","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-023-00578-6"},{"key":"11186","unstructured":"Xie F, Annapureddy N, Chen L, Lobo JL, Oates JC, Shah A, et al. Rheumatoid arthritis and the risk for interstitial lung disease: a comparison of risk associated with biologic and conventional DMARDs. Arthritis Rheumatol 2017; 69: 137."},{"key":"11187","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roac089"},{"key":"11188","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.3640"}],"container-title":["Reumatismo"],"original-title":[],"link":[{"URL":"https:\/\/www.reumatismo.org\/reuma\/article\/download\/1754\/1067","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.reumatismo.org\/reuma\/article\/download\/1754\/1066","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T10:54:25Z","timestamp":1758192865000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.reumatismo.org\/reuma\/article\/view\/1754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":63,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,6,10]]}},"URL":"https:\/\/doi.org\/10.4081\/reumatismo.2025.1754","relation":{},"ISSN":["2240-2683","0048-7449"],"issn-type":[{"value":"2240-2683","type":"electronic"},{"value":"0048-7449","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,29]]}}}